Geniposide effectively safeguards HT22 cells against Aβ-induced damage by activating mitophagy via the PINK1/Parkin signaling pathway
Biochemical Pharmacology · 2024
DOI: 10.1016/j.bcp.2024.116296 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biochemical Pharmacology, 2024. Verfasst von Jiaxi Ye und 6 weiteren Autor:innen. Beteiligte Einrichtung: Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou 510300, PR China. Hauptthemen laut MEDLINE: Amyloid beta-Peptides, Iridoids, Ubiquitin-Protein Ligases, Protein Kinases. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Administration of Traditional Chinese Medicine of Jilin Province, Natural Science Foundation of Guangdong Province.
Abstract (Originalsprache)
Alzheimer's disease (AD) is a neurodegenerative disorder characterized by the significant involvement of amyloid-beta (Aβ) peptide in its pathogenesis. Geniposide, derived from the versatile medicinal of Gardenia jasminoides, is one of the active compounds studied extensively. The objective was to explore the impact of geniposide on Aβ25-35-induced damage in HT22 cells, specifically focusing on its modulation of PINK1/Parkin-mediated mitophagy. In our investigation, geniposide exhibited remarkable restorative effects by enhancing cell viability and preserving the mitochondrial membrane potential. Moreover, it effectively reduced and mitigated the oxidative stress and apoptosis rates induced by Aβ25-35. Notably, geniposide exhibited the capacity to enhance autophagic flux, upregulate LC3II and Beclin-1 expression, and downregulate the expression of p62. Furthermore, geniposide positively influenced the expression of PINK1 and Parkin proteins, with molecular docking substantiating a strong interaction between geniposide and PINK1/Parkin proteins. Intriguingly, the beneficial outcomes of geniposide on alleviating the pronounced apoptosis rates, the overproduction of reactive oxygen species, and diminished the PINK1 and Parkin expression induced by Aβ25-35 were compromised by the mitophagy inhibitor cyclosporine A (CsA). Collectively, these findings suggested that geniposide potentially shields HT22 cells against neurodegenerative damage triggered by Aβ25-35 through the activation of mitophagy. The insights contribute valuable references to the defensive consequences against neurological damage of geniposide, thereby highlighting its potential as a therapeutic intervention in AD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou 510300, PR China.
- Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Guangdong-Hong Kong Joint Laboratory for RNA Medicine, Research Center of Medicine, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen Univ…
- Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou 510300, PR China. Electronic address: huangqih@mail.sysu.edu.cn.
Förderung
- Administration of Traditional Chinese Medicine of Jilin Province
- Natural Science Foundation of Guangdong Province
Zitieren
APA
Ye, J., Wu, J., Ai, L., Zhu, M., Li, Y., Yin, D., & Huang, Q. (2024). Geniposide effectively safeguards HT22 cells against Aβ-induced damage by activating mitophagy via the PINK1/Parkin signaling pathway. Biochemical Pharmacology. https://doi.org/10.1016/j.bcp.2024.116296
Vancouver
Ye J, Wu J, Ai L, Zhu M, Li Y, Yin D, et al. Geniposide effectively safeguards HT22 cells against Aβ-induced damage by activating mitophagy via the PINK1/Parkin signaling pathway. Biochemical Pharmacology. 2024. doi:10.1016/j.bcp.2024.116296
BibTeX
@article{Ye2024,
author = {Ye, Jiaxi and Wu, Jiaying and Ai, Liang and Zhu, Min and Li, Yun and Yin, Dong and Huang, Qihui},
title = {Geniposide effectively safeguards HT22 cells against Aβ-induced damage by activating mitophagy via the PINK1/Parkin signaling pathway},
journal = {Biochemical Pharmacology},
year = {2024},
doi = {10.1016/j.bcp.2024.116296}
}
EUVIMED